LENZ Therapeutics (NASDAQ:LENZ) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of LENZ Therapeutics (NASDAQ:LENZ) from a strong sell rating to a hold rating in a research note issued to investors on Thursday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Piper Sandler lowered their target price on LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday. Weiss Ratings cut LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research note on Tuesday, July 7th. Finally, Citigroup reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.80.

LENZ Therapeutics Trading Up 2.8%

Shares of LENZ stock opened at $4.73 on Thursday. The firm’s fifty day moving average price is $5.64 and its two-hundred day moving average price is $9.01. LENZ Therapeutics has a 1 year low of $4.53 and a 1 year high of $50.40. The firm has a market capitalization of $148.62 million, a P/E ratio of -1.16 and a beta of 0.65.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.03. LENZ Therapeutics had a negative net margin of 586.74% and a negative return on equity of 53.39%. The company had revenue of $5.49 million during the quarter, compared to the consensus estimate of $2.38 million. As a group, equities research analysts forecast that LENZ Therapeutics will post -4.18 EPS for the current fiscal year.

Hedge Funds Weigh In On LENZ Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. C WorldWide Group Holding A S acquired a new position in LENZ Therapeutics during the fourth quarter worth approximately $8,000,000. UBS Group AG lifted its position in shares of LENZ Therapeutics by 30.8% in the fourth quarter. UBS Group AG now owns 1,571,738 shares of the company’s stock valued at $25,148,000 after buying an additional 370,122 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its position in shares of LENZ Therapeutics by 290.8% in the first quarter. Y Intercept Hong Kong Ltd now owns 158,715 shares of the company’s stock valued at $1,452,000 after buying an additional 118,100 shares during the last quarter. Granahan Investment Management LLC boosted its stake in shares of LENZ Therapeutics by 125.2% during the 4th quarter. Granahan Investment Management LLC now owns 431,100 shares of the company’s stock worth $6,898,000 after acquiring an additional 239,703 shares during the period. Finally, Blue Owl Capital Holdings LP bought a new position in shares of LENZ Therapeutics during the 4th quarter worth approximately $2,400,000. Institutional investors own 54.32% of the company’s stock.

Key Stories Impacting LENZ Therapeutics

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: LENZ’s VIZZ prescriptions reportedly increased more than 45% month over month in July, while the company outlined telehealth and national television initiatives intended to support broader product adoption. Lenz outlines July telehealth and national TV push as VIZZ scripts rise over 45% month over month
• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its Q3 2026 EPS forecast to a loss of $1.02 from a loss of $1.15. It also improved its FY2026 estimate to a loss of $4.35 from a loss of $4.74, suggesting somewhat better near-term expectations.
• Neutral Sentiment: The company’s Q2 2026 earnings call focused on VIZZ’s launch progress and commercialization efforts, giving investors additional information about early demand and the strategy for expanding the product’s reach. LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary
• Negative Sentiment: Bank of America downgraded LENZ on concerns that VIZZ’s launch may be slower than expected, a significant issue for a company whose valuation depends on successful commercial execution. Lenz drops as BofA downgrades on a slower VIZZ launch
• Negative Sentiment: HC Wainwright reduced its longer-term EPS forecasts for FY2027 through FY2029 and sharply cut FY2030 EPS to $0.63 from $2.72. Although the firm remains bullish, the revisions imply a slower path to profitability and weigh on the stock’s long-term outlook.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.